Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis - Poll - MDSpire

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

  • By

  • Geert D’Haens

  • Silvio Danese

  • Remo Panaccione

  • David T Rubin

  • Laurent Peyrin-Biroulet

  • Katsuyoshi Matsuoka

  • Edward V Loftus

  • Taku Kobayashi

  • Walid Elsharkawi

  • Rosa Miceli

  • Samia Ahmed

  • Yi Luo

  • Andrew Napoli

  • John Vaile

  • Quentin Dornic

  • Aditya Patel

  • Stefan Schreiber

  • May 13, 2025

  • 0 min

Share

Original Source(s)

Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis

  • by Geert D’Haens, Silvio Danese, Remo Panaccione, David T Rubin, Laurent Peyrin-Biroulet, Katsuyoshi Matsuoka, Edward V Loftus, Taku Kobayashi, Walid Elsharkawi, Rosa Miceli, Samia Ahmed, Yi Luo, Andrew Napoli, John Vaile, Quentin Dornic, Aditya Patel, Stefan Schreiber

  • May 13, 2025

Related Content

Progression of Coronary Calcium Detected on Routine Chest CT Enhances Cardiovascular Risk Assessment in Individuals with Inflammatory Bowel Disease: Findings from a Multicenter Study

Strategies for Organ Regeneration Using Cell Therapy

The role of lipid metabolism and creeping fat in disease assessment and prediction for Crohn’s disease